Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
Quarterly results
DELCATH SYSTEMS, INC. (DCTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, August 14, 2023/PRNewswire/ - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic me...",
"Corporate Presentation"
01/03/2023 8-K Investor presentation
Docs: "Delcath Systems, Inc. corporate presentation",
"Delcath Systems, Inc. corporate presentation"
09/12/2022 8-K Investor presentation
Docs: "Delcath Systems, Inc. corporate presentation dated September 2022",
"Delcath Systems, Inc. corporate presentation dated September 2022"
06/06/2022 8-K Quarterly results
12/02/2021 8-K Quarterly results
01/30/2017 8-K Form 8-K - Current report
08/13/2009 8-K Investor presentation
Docs: "August 13, 2009, Eamonn P. Hobbs presentation at CanAccord Adams Conference",
"August 13, 2009, Eamonn P. Hobbs presentation at CanAccord Adams Conference"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy